Search results
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 23 hours agoPfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its...
Why Pfizer Stock Blasted More Than 6% Higher Today
Motley Fool via Yahoo Finance· 1 day agoPfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied...
Pfizer Inc. (PFE): A New Perspective – Stocks Register
Stocks Register· 1 day agoPfizer Inc. (NYSE:PFE) concluded the trading at $27.18 on Wednesday, May 01, with a rise of 6.09% from its closing price on previous day. Taking a look ...
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been...
Benzinga· 13 hours agoGoldman Sachs maintains the Buy rating with a price target of $31. Bank of America Securities...
7 Dividend Stocks to Buy Now for Steady Returns in Any Market
InvestorPlace· 6 days agoDividend stocks can be a great way to build wealth. If a stock market crash is predicted for the...
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings - ...
Benzinga· 3 days agoPfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has...
Pfizer earnings beat by $0.29, revenue topped estimates By Investing.com
Investing.com· 2 days agoPfizer earnings beat by $0.29, revenue topped estimates
Pfizer stock gains 7% after earnings beat, company calls dividend 'secure'
Yahoo Finance via AOL· 2 days agoPfizer also faces the expiration of patents on some of its biggest drugs, including breast cancer...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 4 days agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
Pfizer beats earnings estimates months after stock dipped to record lows
Crain's New York Business· 1 day agoWhen excluding Pfizer’s Covid products, revenues increased 11%, indicating the success of its $43 billion acquisition of oncology firm Seagen and sales of blockbuster drugs ...